SWOG 1318:贝林妥欧单抗序贯POMP维持治疗初诊费城染色体阴性B细胞急性淋巴细胞白血病老年患者的II期试验
本研究在初诊费城染色体阴性B细胞急性淋巴细胞白血病且年龄≥65岁患者中,评估贝林妥欧单抗诱导和巩固治疗后序贯泼尼松、长春新碱、6-巯基嘌呤和甲氨蝶呤(POMP)维持化疗的疗效与安全性。29例可评估患者中19例(66%;95% CI,46至82)达到完全缓解,3年无病生存率和总生存率估计均为37%。作者认为贝林妥欧单抗耐受良好且有效,包括高危细胞遗传学患者,该方案值得进一步探索。
要点
- 29例初诊费城染色体阴性B-ALL老年患者接受贝林妥欧单抗诱导及巩固后POMP维持治疗。
- 19例(66%;95% CI,46至82)达到完全缓解。
- 3年无病生存率和总生存率估计均为37%(95% CI分别为17至57和20至55)。
核心结论
- 贝林妥欧单抗在初诊费城染色体阴性B-ALL老年患者(包括高危细胞遗传学患者)中耐受良好且有效,3年无病生存率和总生存率结果令人鼓舞,作者认为该方案值得进一步探索。
研究设计与样本
- II期临床试验(SWOG 1318),患者在国家临床试验网络站点接受治疗,纳入年龄≥65岁且初诊费城染色体阴性B-ALL的患者。
- 患者接受贝林妥欧单抗诱导1-2个周期直至达到缓解(完全缓解或伴血细胞计数未完全恢复的完全缓解),随后接受3个周期贝林妥欧单抗巩固治疗,之后接受18个月POMP维持化疗。
- 中枢神经系统预防为鞘内注射甲氨蝶呤8次。
主要发现
- 共纳入29例符合条件的患者,中位年龄75岁,诊断时中位骨髓原始细胞计数87%。
- 10例(34%)细胞遗传学风险为高危,14例接受检测的患者中5例(36%)具有Ph样ALL基因特征。
- 19例(66%;95% CI,46至82)达到完全缓解。
- Kaplan-Meier 3年无病生存率估计为37%(95% CI,17至57),3年总生存率估计为37%(95% CI,20至55)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chemotherapy outcomes in older patients with Philadelphia (Ph) chromosome-negative B-acute lymphoblastic leukemia (ALL) are very poor. Here, we evaluated blinatumomab as induction and consolidation therapy followed by prednisone, vincristine, 6-mercaptopurine, and methotrexate (POMP) maintenance chemotherapy in this patient population. PATIENTS AND METHODS: Patients were treated at National Clinical Trial Network sites. Eligibility criteria included age ≥ 65 years and newly diagnosed Ph chromosome-negative B-ALL. Patients received blinatumomab as induction for one-two cycles until attainment of response (complete remission (CR) and CR with incomplete count recovery). Patients then received three cycles of consolidation with blinatumomab followed by 18 months of POMP maintenance chemotherapy. Eight doses of intrathecal methotrexate were administered as central nervous system prophylaxis. RESULTS: Twenty-nine eligible patients were enrolled. The median age was 75 years, and the median bone marrow blast count at diagnosis was 87%. Cytogenetic risk was poor in 10 patients (34%), and five of 14 patients (36%) tested had the Ph-like ALL gene signature. Nineteen patients (66%; 95% CI, 46 to 82) achieved CR. Kaplan-Meier 3-year disease-free survival and overall survival estimates were 37% (95% CI, 17 to 57) and 37% (95% CI, 20 to 55), respectively. CONCLUSION: Blinatumomab was well tolerated and effective in the treatment of older patients with newly diagnosed Ph chromosome-negative B-ALL, including patients with poor-risk cytogenetics. The 3-year disease-free survival and overall survival results are encouraging and suggest that this approach should be further explored.
引用
- Advani AS, Moseley A, O'Dwyer KM, et al. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022. PMID: 35157496. doi:10.1200/JCO.21.01766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。